Elanco Animal Health Inc (ELAN) Form 8-K — Nov 6, 2026
Elanco Animal Health reported Q3 2026 revenue of $1.265 billion, up 11% year-over-year (9% organic constant currency), with adjusted EPS of $0.27, up 42% from $0.19, and adjusted EBITDA of $243 million, up 23%. Growth was led by Pet Health (up 14%), with Zenrelia and Credelio Quattro reaching record revenue and market-share highs; price contributed 4% growth and adjusted gross margin expanded 300 basis points.
Key figures
- Eps
- $0.04 reported / $0.27 adjusted
- Revenue
- 1265000000
- Guidance
- FY2026 revenue $5.155B-$5.18B; Adjusted EBITDA $1.05B-$1.065B; Adjusted EPS $1.17-$1.20; Q4 revenue $1.19B-$1.215B, Adjusted EBITDA $185M-$200M, Adjusted EPS $0.16-$0.19; innovation revenue target raised to $1.275B; year-end net leverage ~2.9x
- Net Income
- 18000000
- Total Debt
- 3728000000
- Revenue Yoy
- 11% reported / 9% organic constant currency
- Cash Position
- 465000000
- Net Debt
- $3,005 million
- Adjusted Ebitda
- $243 million (+23% YoY)
- Net Leverage Ratio
- 2.9x adjusted EBITDA (down 0.7x vs Dec 31, 2025)
- Pet Health Revenue
- $608 million (+14%)
- Adjusted Net Income
- $136 million (up 45% YoY)
- Farm Animal Revenue
- $631 million (+6% reported / +4% organic CC)
- Operating Cash Flow
- $216 million
- Adjusted Gross Margin
- 56.1% (+300 bps YoY)
- Adjusted Ebitda Margin
- 19.5% (vs 17.5% prior year)
- Trailing Twelve Month Adjusted Ebitda
- $1,053 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.